Not yet available, we are working hard on this format.
View the pre-filled pensThe mechanism
Upstream signals, downstream receptors
The first mechanism is central rather than peripheral. Melanocortin receptors in the brain are involved in a range of signalling, and one compound studied here acts on that system. It is structurally related to a pigmentation compound that European regulators have issued notices about, which is a relationship worth understanding before you read either literature.
The second sits further upstream. Kisspeptin acts on the axis that governs reproductive hormone release, which makes it a research target for questions about how that system is regulated rather than about any downstream outcome.
One of the compounds on this page holds an approval for a specific indication in some jurisdictions. That does not make the research material we supply the same product, and the compound page is explicit about where that line runs.
The heading peptides for libido flattens exactly the distinction this page exists to keep open. One molecule here has been through an approval process for a named indication; the other is a research tool aimed at an upstream signal and studied mostly in animals and in the genetics of receptor mutations. A summary that presents them as two versions of one product is telling you something about the summary rather than about either molecule.
What is being investigated- Melanocortin receptor signalling in the central nervous system
- The reproductive hormone axis and upstream regulation
- Structural relationships between related compounds
- Which compounds hold approvals, and where
Where this sits legally
PT-141 is approved under the name bremelanotide in some jurisdictions for a specific indication. Same molecule name, entirely different product, different obligations attached.
In this area
Compounds studied for libido
Two items, one acting centrally and one acting upstream of the hormone axis.
In depth
Two receptor systems, and the paperwork behind them
Melanocortin receptors occur centrally as well as in the periphery, and which subtype a compound engages is the question that separates the pigmentation work from the arousal work. That an approved product exists at all is a matter of public record rather than opinion: the trials filed under the name bremelanotide can be read among the registry entries on ClinicalTrials.gov. What we supply is not that product, and the shared molecule name does nothing to close the gap between the two.
The combination sold in this area contains a second molecule working through an entirely separate receptor system, set out on the oxytocin page; pairing them is a convenience for protocols that call for both and not a claim about the pair. On the upstream side, most of what is understood about kisspeptin comes from animal models and from what happens when the receptor is defective, which is narrow evidence but unusually clean. For the material itself, the comparison of spray and injection routes covers what each of the two formats in this area changes.
Where we stop
What the libido page leaves out
No outcome claims of any kind, which in this area matters more than most. One compound here is structurally related to something regulators have published notices about, and another holds an approval elsewhere that does not transfer to research material. We keep those two facts visible rather than letting them blur.
Background reading
The libido reading list, before you order
Four pages, including the regulatory notices on the structurally related compound.
Compound
PT-141
Filed under bremelanotide in the literature; structurally a close cousin of melanotan 2.
Read CompoundKisspeptin
A peptide upstream of the reproductive hormone axis, and why that position makes it interesting.
Read CompoundMelanotan 2
The structurally related compound, including the regulatory notices published about it.
Read FrameworkResearch use only
The legal category this material sits in, and what that permits.
ReadFrequently asked
Questions about libido research
Almost always about the line between an approved medicine and research material.